Drug intelligence / Profile preview

V330

Development stage: Phase 1
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

V330 is an investigational prophylactic vaccine developed to stimulate the immune system against norovirus infection. It is currently being evaluated in Phase 1 clinical trials for its safety, tolerability, and immunogenicity in healthy adults aged 18 to 79 years. The vaccine works by inducing the production of antibodies that block histo-blood group antigen (HBGA) binding of norovirus virus-like particles (VLPs), which are critical for viral entry into host cells. The primary goal is to prevent norovirus infection by generating a robust immune response through immunostimulation[1][2][3].

Targets

Norovirus VP1

Beyond the preview

Go deeper on V330.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V330.

Explore the full profile